Bexarotene-induced hypothyroidism and dyslipidemia; a nation-wide study
Central hypothyroidism and dyslipidemia are well-known adverse events (AEs) of bexarotene therapy. Although hypothyroidism is known to cause dyslipidemia, no study has examined the association between hypothyroidism and dyslipidemia in patients undergoing bexarotene therapy. The aim of this study is...
Saved in:
| Main Authors: | Katsunori Manaka, Junichiro Sato, Yusuke Hikima, Hirofumi Horikoshi, Maho Taguchi, Akimichi Morita, Hiraku Suga, Hikari Boki, Taku Fujimura, Yoji Hirai, Takatoshi Shimauchi, Chiharu Tateishi, Eiji Kiyohara, Ikko Muto, Hideki Nakajima, Riichiro Abe, Kazuyasu Fujii, Chikako Nishigori, Eiji Nakano, Kentaro Yonekura, Takeru Funakoshi, Masahiro Amano, Tomomitsu Miyagaki, Reiko Yamashita, Makoto Sugaya, Toshihisa Hamada, Masaomi Nangaku, Taroh Iiri, Noriko Makita |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Japan Endocrine Society
2024-08-01
|
| Series: | Endocrine Journal |
| Subjects: | |
| Online Access: | https://www.jstage.jst.go.jp/article/endocrj/71/8/71_EJ23-0699/_html/-char/en |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comparison of the efficacy of treatment with clobetasol propionate or bexarotene in early-stage mycosis fungoides
by: Aslı Aksu Çerman, et al.
Published: (2025-04-01) -
Bexarotene ameliorated the pulmonary inflammation and M1 polarization of alveolar macrophages induced by cigarette smoke via PPARγ/HO-1
by: Haoshen Feng, et al.
Published: (2024-12-01) -
The protective effects of bexarotene against advanced glycation end-product (AGE)-induced degradation of articular extracellular matrix (ECM)
by: Zhuqing Zha, et al.
Published: (2020-01-01) -
Medicinal Perspectives of Retinoids (Review)
by: L. V. Kovalenko, et al.
Published: (2023-12-01) -
Mogamulizumab in combination improves clinical outcomes in relapsed and refractory Sézary syndrome
by: Jordan Pilkington, et al.
Published: (2025-05-01)